Welcome to our dedicated page for Maximus news (Ticker: MMS), a resource for investors and traders seeking the latest updates and insights on Maximus stock.
Maximus, Inc. reports developments tied to its role as a provider of tech-enabled government services for public programs. The company supports government agencies with business process management, technology solutions, health insurance eligibility and enrollment programs, clinical services, assessments, appeals and independent medical reviews across U.S. Federal Services, U.S. Services and international operations.
Recurring news includes fiscal results, guidance updates, sales-pipeline commentary, segment trends, clinical program demand and productivity initiatives. Company updates also cover AI-enabled tools such as Accuracy Assistant for state SNAP programs, quarterly cash dividends, common-stock repurchase authorizations and governance changes involving senior legal and corporate-secretary roles.
Summary not available.
Summary not available.
Maximus (NYSE: MMS) has announced a quarterly cash dividend of $0.28 per share, set for payment on May 31, 2023. Shareholders on record as of May 15, 2023 will be eligible to receive this dividend. This decision reflects the company's commitment to returning value to its shareholders while maintaining its strategic focus on improving public service delivery.
Maximus operates as a key provider of government services globally, tackling complex challenges in technology, health, economics, and social sectors. Their innovative approach helps enhance productivity and efficiency in government-sponsored programs, ensuring better outcomes for the public.
Maximus (NYSE: MMS) is scheduled to release its financial results for the three and six months ended March 31, 2023, after market close on May 3, 2023. A conference call will follow on May 4, 2023, at 9:00 a.m. ET, allowing shareholders to submit questions by email until one hour prior. The call is accessible via webcast or by phone. For those unable to attend live, a recording will be available on Maximus's investor site.
Maximus (MMS) reported Q1 FY2023 financial results, with revenue increasing 8.5% to $1.25 billion and organic growth at 10.3%. Diluted EPS was $0.65, with adjusted EPS at $0.94. Due to the scheduled restart of Medicaid redeterminations, the company raised its FY23 revenue guidance to $4.85-$5.0 billion and adjusted EPS guidance to $4.00-$4.30. U.S. Services revenue rose 13.7% to $439.5 million, while the operating margin decreased to 8.6%. The cash dividend of $0.28 per share will be paid on February 28, 2023. Maximus remains focused on capturing growth in government services amid a recovery from pandemic-related challenges.
Maximus (NYSE: MMS) has declared a quarterly cash dividend of $0.28 per share, scheduled for payment on February 28, 2023. Shareholders of record on February 15, 2023 will receive this dividend. As a prominent provider of government services globally, Maximus aims to enhance public service delivery through innovative business process management and technology solutions.
Maximus (NYSE: MMS) will release its financial results for the three months ended December 31, 2022, after market close on February 8, 2023. A conference call will follow on February 9, 2023, at 9:00 a.m. ET, where shareholders can submit questions via email. The call will be accessible to the public through a webcast and by phone. Maximus is a global leader in government services, focusing on improving public service delivery through innovative solutions and operational excellence.
Maximus (NYSE: MMS) has secured a $100 million contract with the Centers for Disease Control and Prevention (CDC) for one base year plus four option years. The contract aims to enhance the CDC-INFO program, providing vital health information to Americans. Maximus will utilize its technology and operational expertise to improve service delivery, especially post-COVID-19. The company has previously supported the CDC-VAX program during the pandemic, earning multiple awards for its efforts.
Maximus (NYSE: MMS) announced it will release its financial results for the fiscal year and quarter ending September 30, 2022, after market close on November 21, 2022. A conference call will follow on November 22, 2022, at 9:00 a.m. ET. Shareholders can submit questions for management via email until one hour prior to the call. The event will be accessible to the public through a webcast and by phone.
Maximus (NYSE:MMS) has announced the transition of Dr. Arvenita W. Cherry to the role of President of the Maximus Foundation, effective October 1. She succeeds Dr. John Boyer, who served for 17 years and will remain as Chairman until his retirement later this fiscal year. The Maximus Foundation is dedicated to supporting community and healthcare initiatives, recently distributing $2 million in grants to 167 nonprofits in the U.S. Dr. Cherry aims to align the foundation’s focus with the company’s diversity, equity, and inclusion strategies.